Trial Profile
Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TOP 1501
- 01 Feb 2022 Results assessing perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer, published in the Journal of Thoracic and Cardiovascular Surgery
- 01 Nov 2019 Planned End Date changed from 1 Jan 2027 to 1 Mar 2026.
- 12 Feb 2019 Status changed from recruiting to active, no longer recruiting.